Clinical Trials Logo

Filter by:
NCT ID: NCT03449199 Completed - Clinical trials for Diabetic Kidney Disease

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

Start date: April 10, 2018
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the effect of 2 dose levels of TMX-049 on urinary albumin excretion in subjects with Type 2 diabetes and albuminuria (a urinary albumin-to-creatinine ratio (UACR) 200 to 3000 mg/g and an estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.73m2). Effects of each TMX-049 dose on UACR will be assessed in terms of ratios using log-transformed UACR at Baseline and after a 12-week period of treatment.

NCT ID: NCT03451422 Completed - Clinical trials for Systemic Lupus Erythematosus

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

Start date: April 10, 2018
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin Alfa in participants with systemic lupus erythematosus (SLE).

NCT ID: NCT03463759 Completed - Healthy Clinical Trials

Pain Inhibition and Facilitation in Recurrent Low Back Pain

Start date: April 10, 2018
Phase:
Study type: Observational

This study evaluates psychophysical measures of pain inhibition and facilitation, along with cortical responses to different sensory stimuli, in patients with recurrent low back pain and matched healthy individuals.

NCT ID: NCT03465904 Completed - Migraine Clinical Trials

A Phase III Trial of e-TNS for the Acute Treatment of Migraine

TEAM
Start date: April 10, 2018
Phase: N/A
Study type: Interventional

The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack. This randomized, double-blind, sham-controlled trial will study the abortive treatment of migraine using the Cefaly® Abortive Program device.

NCT ID: NCT03473301 Completed - Cerebral Palsy Clinical Trials

A Study of UCB and MSCs in Children With CP: ACCeNT-CP

ACCeNT-CP
Start date: April 10, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in children with cerebral palsy. In addition, this study will contribute much needed data to the clinical trials community on the natural history of the motor function in CP over short-term (less than 1 year) time periods relevant to the conduct of clinical trials and assess the safety of AlloCB and hCT-MSC infusion in children with cerebral palsy.

NCT ID: NCT03473925 Completed - Clinical trials for Non-small Cell Lung Cancer

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Start date: April 10, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive refractory non-small cell lung cancer (NSCLC), castration resistant prostate cancer (CRPC) or microsatellite stable (MSS) colorectal cancer (CRC).

NCT ID: NCT03483506 Completed - Healthy Clinical Trials

This Study in Healthy Men Tests How the Body Takes up BI 1467335

Start date: April 10, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of this trial is to investigate the absolute bioavailability of BI 1467335 with an intravenous microdose formulation containing labelled [C-14] BI 1467335 and an unlabelled oral tablet formulation of BI 1467335 in healthy male subjects. The secondary objective is the evaluation of additional pharmacokinetic parameters following the two treatments.

NCT ID: NCT03485014 Completed - Clinical trials for Postoperative Pain Management

Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

Start date: April 10, 2018
Phase: Phase 1
Study type: Interventional

Primary objective: The primary objective of this study is to evaluate the pharmacokinetics (PK) of EXPAREL in pediatric subjects 12 to less than 17 years of age undergoing spinal surgery. Secondary objective: The secondary objective of this study is to evaluate the safety of EXPAREL in pediatric subjects 12 to less than 17 years of age undergoing spinal surgery.

NCT ID: NCT03487172 Completed - Knee Clinical Trials

Sculptra Aesthetic for the Treatment of Upper Knee Skin Laxity

Start date: April 10, 2018
Phase: N/A
Study type: Interventional

All subjects will receive three, single-sided injections of PLLA, performed 1 month apart.

NCT ID: NCT03490734 Completed - Obesity Clinical Trials

Neurobehavioral Plasticity to Regular Sugar-Sweetened Beverage Intake: An fMRI Experiment

Start date: April 10, 2018
Phase: N/A
Study type: Interventional

The proposed project will examine the strength, specificity and persistence of neurobehavioral adaptions that occur in the initial period of repeated consumption of a branded sugar sweetened beverage (SSB).